Durvalumab Plus Chemotherapy Improves Gastric Cancer Survival in MATTERHORN Trial

Final results from the Phase 3 MATTERHORN trial, published in The Lancet, indicate that adding perioperative durvalumab to standard chemotherapy significantly reduced the risk of death by 22% for patients with resectable gastric or gastroesophageal junction cancer. This finding supports the new combination as a potential standard treatment option, offering improved overall survival for this patient population.